Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.18.8377

Association of PNPLA3 Polymorphism with Hepatocellular Carcinoma Development and Prognosis in Viral and Non-Viral Chronic Liver Diseases  

Khlaiphuengsin, Apichaya (Department of Biochemistry Research Unit of Hepatitis and Liver Cancer, Chulalongkorn University)
Kiatbumrung, Rattanaporn (Department of Biochemistry Research Unit of Hepatitis and Liver Cancer, Chulalongkorn University)
Payungporn, Sunchai (Department of Biochemistry Research Unit of Hepatitis and Liver Cancer, Chulalongkorn University)
Pinjaroen, Nutcha (Department of Radiology, Faculty of Medicine, Chulalongkorn University)
Tangkijvanich, Pisit (Department of Biochemistry Research Unit of Hepatitis and Liver Cancer, Chulalongkorn University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.18, 2016 , pp. 8377-8382 More about this Journal
Abstract
Background: The aim of this study was to evaluate any association between a single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain containing 3 (PNPLA3) (rs738409, C>G) and the development and prognosis in patients with hepatocellular carcinoma (HCC). Materials and Methods: Two hundred heathy controls and 388 HCC cases were included: 211 with HBV, 98 patients with HCV, 29 with alcoholic steatohepatitis (ASH) and 52 with non-alcoholic steatohepatitis (NASH). The SNP was determined by real-time PCR based on TaqMan assays. Results: The prevalence of rs738409 genotypes CC, CG and GG in controls was 91 (45.5%), 88 (44.0%), and 21 (10.5%), respectively, while the corresponding genotypes in all patients with HCC was 158 (40.7%), 178 (45.9%), and 52 (13.4%). The GG genotype had significantly higher distribution in patients with ASH/NASH-related HCC compared with controls (OR=2.34, 95% CI=1.16-4.71, P=0.018), and viral-related HCC cases (OR=2.15, 95% CI=1.13-4.08, P=0.020). However, the frequency of the GG genotype was similar between controls and patients with viral-related HCC. At initial diagnosis, HBV-related HCC were larger and at more advanced BCLC stage than the other HCC groups. There were no significant differences between the GG and non-GG groups regarding clinical characteristics, tumor stage and overall survival. Conclusions: These data suggest an influence of the PNPLA3 polymorphism on the occurrence of HCC in patients with ASH/NASH but not among those with chronic viral hepatitis. However, the polymorphism was not associated with the prognosis of HCC.
Keywords
PNPLA3; HBV; HCV; ASH; NASH; HCC development; prognosis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Brouwer WP, van der Meer AJ, Boonstra A, et al (2015). The impact of PNPLA3 (rs738409 C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver Int, 35, 438-47.   DOI
2 Bruix J, Sherman M (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2.   DOI
3 Day CP (2006). From fat to inflammation. Gastroenterology, 130, 207-10.   DOI
4 Falleti E, Fabris C, Cmet S, et al (2011). PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int, 31, 1137-43.   DOI
5 Friedrich K, Wannhoff A, Kattner S, et al (2014). PNPLA3 in end-stage liver disease: alcohol consumption, hepatocellular carcinoma development, and transplantation-free survival. J Gastroenterol Hepatol, 29, 1477-84.   DOI
6 Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma--current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.   DOI
7 Guyot E, Sutton A, Rufat P, et al (2013). PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. J Hepatol, 58, 312-8.   DOI
8 He S, McPhaul C, Li JZ, et al (2010). A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem, 285, 6706-15.   DOI
9 Huang Y, He S, Li JZ, et al (2010). A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc Natl Acad Sci U S A, 107, 7892-7.   DOI
10 Jenkins CM, Mancuso DJ, Yan W, et al (2004). Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J Biol Chem, 279, 48968-75.   DOI
11 Jin F, Xiong WJ, Jing JC, et al (2011). Evaluation of the association studies of single nucleotide polymorphisms and hepatocellular carcinoma: a systematic review. J Cancer Res Clin Oncol, 137, 1095-104.   DOI
12 Nischalke HD, Berger C, Luda C, et al (2011). The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One, 6, 27087.   DOI
13 Liu YL, Patman GL, Leathart JB, et al (2014). Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol, 61, 75-81.   DOI
14 Llovet JM, Di Bisceglie AM, Bruix J, et al (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst, 100, 698-711.   DOI
15 Nault JC (2014). Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol, 28, 937-47.   DOI
16 Patton HM, Patel K, Behling C, et al (2004). The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol, 40, 484-90.
17 Pingitore P, Pirazzi C, Mancina RM, et al (2014). Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta, 1841, 574-80.   DOI
18 Romeo S, Kozlitina J, Xing C, et al (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet, 40, 1461-5.   DOI
19 Rubbia-Brandt L, Quadri R, Abid K, et al (2000). Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol, 33, 106-15.   DOI
20 Salameh H, Raff E, Erwin A, et al (2015). PNPLA3 Gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. The American journal of gastroenterology, 110, 846-56.   DOI
21 Sookoian S, Castano GO, Burgueno AL, et al (2009). A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res, 50, 2111-6.   DOI
22 Sato M, Kato N, Tateishi R, et al (2014). Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Hepatol Res, 44, 137-44.   DOI
23 Singal AG, Manjunath H, Yopp AC, et al (2014). The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. The American journal of gastroenterology, 109, 325-34.   DOI
24 Smagris E, BasuRay S, Li J, et al (2015). Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology, 61, 108-18.   DOI
25 Sopipong W, Tangkijvanich P, Payungporn S, et al (2013). The KIF1B (rs17401966) single nucleotide polymorphism is not associated with the development of HBV-related hepatocellular carcinoma in Thai patients. Asian Pac J Cancer Prev, 14, 2865-9.   DOI
26 Stickel F, Buch S, Lau K, et al (2011). Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology, 53, 86-95.   DOI
27 Takeuchi Y, Ikeda F, Moritou Y, et al (2013). The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol, 48, 405-12.   DOI
28 Tangkijvanich P, Hirsch P, Theamboonlers A, et al (1999). Association of hepatitis viruses with hepatocellular carcinoma in Thailand. J Gastroenterol, 34, 227-33.   DOI
29 Trepo E, Nahon P, Bontempi G, et al (2014). Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 59, 2170-7.   DOI
30 Trepo E, Guyot E, Ganne-Carrie N, et al (2012). PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology, 55, 1307-8.   DOI
31 Trepo E, Pradat P, Potthoff A, et al (2011). Impact of patatinlike phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology, 54, 60-9.   DOI
32 Valenti L, Motta BM, Soardo G, et al (2013). PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. PLoS One, 8, 75982.   DOI
33 Vigano M, Valenti L, Lampertico P, et al (2013). Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B. Hepatology, 58, 1245-52.   DOI
34 Yuan X, Waterworth D, Perry JR, et al (2008). Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am J Hum Genet, 83, 520-8.   DOI
35 Zampino R, Coppola N, Cirillo G, et al (2015). Patatin-Like Phospholipase Domain-Containing 3 I148M variant is associated with liver steatosis and fat distribution in Chronic Hepatitis B. Dig Dis Sci.